Apyrase to treat ischemia/reperfusion injury during lung transplantation

Award Information
Agency:
Department of Health and Human Services
Amount:
$839,863.00
Program:
SBIR
Contract:
2R44HL087456-02
Solitcitation Year:
2009
Solicitation Number:
PHS2009-2
Branch:
N/A
Award Year:
2009
Phase:
Phase II
Agency Tracking Number:
HL087456
Solicitation Topic Code:
N/A
Small Business Information
APT THERAPEUTICS, INC.
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
Y
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
192266141
Principal Investigator
 RIDONG CHEN
 (314) 608-6932
 RCHEN@NIDUSCENTER.COM
Business Contact
 RIDONG CHEN
Phone: (314) 812-8054
Email: rchen@niduscenter.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vascular integrity and inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics approach, we have successfully engineered an optimized human apyrase, APT102. With Phase II grant support, We will determine whether APT102 improves lung allograft function without increasing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs. The ultimate goal is to demonstrate whether APT102 has the potential to be a therapy for transplantation-associated and other vascular diseases. PUBLIC HEALTH RELEVANCE: We will determine whether human apyrase improves lung allograft function without increasing bleeding risk in clinically relevant models of allogeneic orthotopic lung transplantation in rats and dogs.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government